WO2012112869A3 - Thérapie anticancéreuse ciblée utilisant des inhibiteurs de la transcription d'ets - Google Patents

Thérapie anticancéreuse ciblée utilisant des inhibiteurs de la transcription d'ets Download PDF

Info

Publication number
WO2012112869A3
WO2012112869A3 PCT/US2012/025608 US2012025608W WO2012112869A3 WO 2012112869 A3 WO2012112869 A3 WO 2012112869A3 US 2012025608 W US2012025608 W US 2012025608W WO 2012112869 A3 WO2012112869 A3 WO 2012112869A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapy
targeted cancer
transcriptional inhibitors
ets
ets transcriptional
Prior art date
Application number
PCT/US2012/025608
Other languages
English (en)
Other versions
WO2012112869A2 (fr
Inventor
Xiaobo CAO
William Roy SMYTHE
Dawit GIZACHEW
Original Assignee
Scott & White Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Healthcare filed Critical Scott & White Healthcare
Publication of WO2012112869A2 publication Critical patent/WO2012112869A2/fr
Publication of WO2012112869A3 publication Critical patent/WO2012112869A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne généralement des procédés et des compositions de traitement d'un individu atteint du cancer en utilisant des polypeptides mutants de TEL. Dans des modes de réalisation particuliers, les peptides ou polypeptides TEL qui sont utilisés présentent des mutations au niveau d'un ou plusieurs sites de phosphorylation, d'acétylation, de glycosylation, d'ubiquitination, ou de sumoylation, par exemple.
PCT/US2012/025608 2011-02-17 2012-02-17 Thérapie anticancéreuse ciblée utilisant des inhibiteurs de la transcription d'ets WO2012112869A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443918P 2011-02-17 2011-02-17
US61/443,918 2011-02-17

Publications (2)

Publication Number Publication Date
WO2012112869A2 WO2012112869A2 (fr) 2012-08-23
WO2012112869A3 true WO2012112869A3 (fr) 2012-10-11

Family

ID=46673197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025608 WO2012112869A2 (fr) 2011-02-17 2012-02-17 Thérapie anticancéreuse ciblée utilisant des inhibiteurs de la transcription d'ets

Country Status (1)

Country Link
WO (1) WO2012112869A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507722D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREEN ET AL.: "DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 24, 11 June 2010 (2010-06-11), pages 18498 - 18504 *
MAKI ET AL.: "Leukemia-related transcription factor TEL is negatively regulated through extracellular signal-regulated kinase-induced phosphorylation", MOLECULAR AND CELLULAR BIOLOGY, vol. 24, no. 8, April 2004 (2004-04-01), pages 3227 - 3237 *
ROUKENS ET AL.: "Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function", MOLECULAR AND CELLULAR BIOLOGY, vol. 28, no. 7, April 2008 (2008-04-01), pages 2342 - 4357 *
WOOD ET AL.: "Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor", PNAS, vol. 100, no. 6, 18 March 2003 (2003-03-18), pages 3257 - 3262 *

Also Published As

Publication number Publication date
WO2012112869A2 (fr) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2021010482A (es) Compuestos y metodos para la degradacion mejorada de proteinas especificas.
MX2021012926A (es) Moduladores de la proteolisis basados en imida y metodos de uso asociados.
MX2018000471A (es) Moduladores de proteolisis basados en alanina y metodos de uso asociados.
EP3976195A4 (fr) Méthodes de traitement de cancers neuroendocriniens à petites cellules et de cancers associés
MX2022009478A (es) Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
WO2012058241A3 (fr) Procédés et compositions pour amélioration du cancer du pancréas
WO2015070020A3 (fr) Polythérapie pour le traitement du cancer utilisant des inhibiteurs de protéine à bromodomaine et à domaine extra-terminal (bet)
WO2013123432A3 (fr) Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
PH12020500225A1 (en) Anti- cd137 antibodies
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
WO2009094172A3 (fr) Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire
HUE036224T2 (hu) C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra
WO2011159685A3 (fr) Inhibition de l'interaction de la protéine wdr5 avec ses partenaires de liaison et méthodes thérapeutiques associées
WO2011146810A3 (fr) Raccord céramique-céramique et procédés associés
WO2008061020A3 (fr) Méthodes permettant de traiter, de diagnostiquer ou de détecter un cancer
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
IL284561A (en) Neoantigens of the prostate and their uses
WO2014058866A3 (fr) Traitement de la sclérose latérale amyotrophique
WO2009158374A3 (fr) Inhibiteurs d’activité akt
EP3476401A4 (fr) Inducteur de mort cellulaire, inhibiteur de la prolifération cellulaire et composition pharmaceutique destinée au traitement d'une maladie associée à une prolifération cellulaire anormale
WO2015009820A3 (fr) Peptides et analogues peptidiques protecteurs tissulaires permettant de prévenir et traiter des maladies et des troubles associés à une lésion tissulaire
EP3981880A4 (fr) Construction d'adn pour le diagnostic et le traitement du cancer
EP3759074A4 (fr) Petites molécules destinées à traiter le cancer, inhiber l'activité d'une chimiokine et/ou induire la mort cellulaire
WO2012112869A3 (fr) Thérapie anticancéreuse ciblée utilisant des inhibiteurs de la transcription d'ets

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12746829

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12746829

Country of ref document: EP

Kind code of ref document: A2